Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06644378 | A Study of [14C]-LY3866288 in Healthy Participants | PHASE1 | COMPLETED | 15 | — | — | Oct 28, 2024 | Jan 3, 2025 | Jan 22, 2025 | 1 | United States |
| NCT06641037 | A Study of LY3866288 in Healthy Participants | PHASE1 | COMPLETED | 15 | — | — | Oct 17, 2024 | Dec 2, 2024 | Apr 1, 2025 | 1 | United States |
PK: AUC From Time 0 to the Time of the Last Quantifiable Concentration of LY3866288
PK: Cmax of LY3866288
| Arm | Type | Description |
|---|---|---|
| Part A: [14C]-LY3866288 | EXPERIMENTAL | Single dose of \[¹⁴C\]-LY3866288 administered orally. |
| Part B: LY3866288 + [14C]-LY3866288 | EXPERIMENTAL | Single dose of LY3866288 administered orally followed by a single dose of \[¹⁴C\]-LY3866288 administered intravenously (IV). |
| LY3866288 Cohort 1 (High-Fat Meal) | EXPERIMENTAL | LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort |
| LY3866288 Cohort 2 (Low-Fat Meal) | EXPERIMENTAL | LY3866288 single and multiple capsules administered orally under fasted/fed conditions in cross-over manner within cohort |
| Name | Type | Description |
|---|---|---|
| [14C]-LY3866288 | DRUG | Administered orally. |
| LY3866288 | DRUG | Administered orally. |
Inclusion Criteria: * Male and female participants who are overtly healthy determined by medical history, physical examination, 12-lead ECGs, vital signs measurements, and clinical laboratory evaluations at screening and/or check-in by the investigator * Have Body mass index between 18.0 and 32.0 k...